Skip to main content

Table 2 Serious adverse events (SAE) by treatment group

From: Mycophenolate mofetil and tacrolimus versus tacrolimus alone for the treatment of idiopathic membranous glomerulonephritis: a randomised controlled trial

 

TAC

TAC/MMF

Patients with at least 1 SAE

7

3

Total number of SAEs

12

6

Diarrhoea/vomiting

3

2

High INR/Bleeding/Anaemia

 

2

Haemorrhoidectomy

 

1

Haematuria/ Urinary tract infection

2

 

Blackout

1

 

AKI

3

 

Headache

1

 

Infection

1

 

Gouty arthritis

1

 

Cholestatic jaundice

 

1

  1. In the TAC group 3/12 SAEs were possibly related to trial drug, 3/12 were unlikely to be related to trial drug and the rest (6/12) were not related to trial drug. None of the 6 SAEs reported in the TAC/MMF group were related to trial drugs.
  2. AKI acute kidney injury
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us